CXCL1 and ovarian cancer: Aberrant upregulation of CXCR1/2 is attributed to augmented tumor progression in ovarian cancers, evincing that GROα mediates the oncogenic capacities of cancer invasion and migration by interacting with CXCR1/2 in OvCa [42, 44, 45].